Loading
Adela's study of about 7,000 people building a blood test that reads DNA methylation to find many cancers early and to track cancer after treatment.
CAMPERR (NCT05366881) is an observational study sponsored by Adela, Inc. It trains and validates a genome-wide methylome enrichment platform to detect multiple cancer types and tell them apart, and to detect residual disease after treatment.
The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 7,000 participants, a start on 3 May 2022 and primary completion expected in March 2026.
Shares Multi-cancer early detection (MCED), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/